[Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations].
The discovery of an inducible form of cyclooxygenase (COX-2) requires a refinement of the theory that inhibition of cyclooxygenase activity explains both therapeutic effects and side-effects of non-steroidal anti-inflammatory drugs (NSAIDs). Selective COX-2 inhibitors have demonstrated in clinical trials a significantly better gastrointestinal tolerability than classical NSAIDs, for the same anti-inflammatory activity. Their tolerability in patients with active ulcer or with a recent history of ulcer as well as in patients suffering from cardiovascular or renal diseases has still to be investigated in detail. Their therapeutic potential in several new indications, including pre-term labour, colorectal cancer and Alzheimer's disease, is currently being investigated.
Pairet
M
M
Boehinger Ingelheim Pharma KG, Dept of Pulmonary Research, Ingelheim am Rhein, Germany.
Netter
P
P
D000544:Alzheimer Disease / Q000517:prevention & control; D000700:Analgesics / Q000145:classification / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000145:classification / Q000494:pharmacology; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001095:Arachidonic Acids / Q000378:metabolism; D001665:Binding Sites / Q000187:drug effects; D000068579:Celecoxib; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000517:prevention & control; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004790:Enzyme Induction / Q000187:drug effects; D005753:Gastric Mucosa / Q000187:drug effects; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects; D007527:Isoenzymes / Q000096:biosynthesis / Q000737:chemistry / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects; D007783:Lactones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008563:Membrane Lipids / Q000378:metabolism; D008565:Membrane Proteins; D051379:Mice; D010437:Peptic Ulcer / Q000139:chemically induced; D010743:Phospholipids / Q000378:metabolism; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis / Q000737:chemistry / Q000494:pharmacology*; D011453:Prostaglandins / Q000096:biosynthesis; D011720:Pyrazoles; D012098:Reproduction / Q000187:drug effects; D012449:Safety; D013379:Substrate Specificity; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013450:Sulfones; D014633:Valine / Q000737:chemistry
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D001095:Arachidonic Acids; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008563:Membrane Lipids; D008565:Membrane Proteins; D010743:Phospholipids; D011453:Prostaglandins; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D014633:Valine; D000068579:Celecoxib